Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 5,556 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Recruiting Phase 3 Interventional

Zilucoplan for Severe gMG Exacerbations

NCT07215949
View directory record Official record
Conditions
Generalized Myasthenia Gravis (gMG)
Interventions
Zilucoplan®
Drug
Lead sponsor
Miriam Freimer
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Tampa, Florida • Kansas City, Kansas • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Studies of Autistic Patients: Gene Networks and Clinical Subtypes

NCT01092208
View directory record Official record
Conditions
Autism, Tuberous Sclerosis
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
4 Years to 18 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 13, 2026, 6:37 PM EDT
Terminated Not applicable Interventional Results available

Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome

NCT01817517
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Medtronic Activa Deep Brain Stimulation System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Enrolling by invitation Phase 1 Interventional

PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis

NCT07771621
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
[18F]Fluselenamyl (FSA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 3 Interventional Results available

Impact of Switching to Continuous Release Dopamine Agonists

NCT00465452
View directory record Official record
Conditions
Parkinson Disease
Interventions
Continuous Release Dopamine Agonists
Drug
Lead sponsor
University of Toledo
Other
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 13, 2026, 6:37 PM EDT
Recruiting Not applicable Interventional

Scrambler Therapy for Corticobasal Syndrome-Associated Pain

NCT05653778
View directory record Official record
Conditions
Corticobasal Degeneration, Corticobasal Syndrome, Pain, Neuropathic
Interventions
Scrambler therapy, TENS treatment
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Not applicable Interventional

Improving Sleep and Cognition in Alzheimer's Disease

NCT05200208
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Citicoline supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Recruiting No phase listed Observational

Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension

NCT06747884
View directory record Official record
Conditions
Congenital Myotonic Dystrophy, Childhood Myotonic Dystrophy, Myotonic Dystrophy
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
3 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Little Rock, Arkansas • Kansas City, Kansas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

African American Alzheimer's Progression Markers - CSF and Neuro-Imaging

NCT02089555
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Lumbar puncture, Blood draw, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
Emory University
Other
Eligibility
60 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 13, 2026, 6:37 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

NCT05231785
View directory record Official record
Conditions
Early-Onset Alzheimer Disease
Interventions
ALN-APP, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
La Jolla, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Speech-Language Treatment With Remotely Supervised Transcranial Direct Current Stimulation in Primary Progressive Aphasia

NCT05901233
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS), Remotely supervised sham tDCS (RS-sham-tDCS), Lexical Retrieval Training (LRT), Video Implemented Script Training in Aphasia (VISTA)
Device · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
San Francisco, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 13, 2026, 6:37 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases

NCT04529252
View directory record Official record
Conditions
Spinocerebellar Ataxias, Cerebellar Ataxia, Nucleotide Repeat Disease
Interventions
Specimen collection
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

CNS Uptake of Intranasal Glutathione

NCT02324426
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Reduced Glutathione
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 13, 2026, 6:37 PM EDT
Not yet recruiting Not applicable Interventional

iBCI Optimization for Veterans With Paralysis

NCT05470478
View directory record Official record
Conditions
Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome, Muscular Dystrophy
Interventions
Mobile neural decoding platform (mobile iBCI)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer

NCT04273243
View directory record Official record
Conditions
CLN6, Batten Disease
Interventions
AT-GTX-501
Genetic
Lead sponsor
Emily de los Reyes
Other
Eligibility
12 Months and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 3 Interventional

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

NCT00199368
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline ( KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 13, 2026, 6:37 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

NCT02051764
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Florbetapir F 18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Newport Beach, California • Orange, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 13, 2026, 6:37 PM EDT
Active, not recruiting Phase 3 Interventional

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

NCT02962414
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

Buspirone in Parkinson's Disease

NCT02803749
View directory record Official record
Conditions
Parkinson Disease, Anxiety
Interventions
Buspirone, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 13, 2026, 6:37 PM EDT
Completed No phase listed Observational

Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)

NCT00104585
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients

NCT00110552
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Salvia officinalis (sage)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Not applicable Interventional

Kinesia 360 Parkinson's Monitoring Study

NCT02657655
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Kinesia 360
Device
Lead sponsor
Great Lakes NeuroTechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Not applicable Interventional

Auditory Neural Function in Implanted Patients With Usher Syndrome

NCT04906135
View directory record Official record
Conditions
Usher Syndrome, Cochlear Implantation
Interventions
Experimental manipulation of stimulation parameters
Other
Lead sponsor
Ohio State University
Other
Eligibility
1 Year to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 2 Interventional

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01486849
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK-2017357, Placebo, Riluzole 50 MG
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Fresno, California • La Jolla, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 13, 2026, 6:37 PM EDT